MedTrace Logo

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

NCT05681949 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2023-08-24

No results posted yet for this study

Summary

The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with hepatobiliary tumors. The main questions it aims to answer are:

Can ADBoard achieve a high level of similar recommendations as physicians' tumor conferences? Can ADBoard consider a more complete set of patient-related data than in physicians' tumor conferences? Can ADBoard reduce the time between the first time the patient is discussed at the tumor conference and the start of the recommended treatment plan? Participants will have their hepatobiliary tumor treatments determined by either tumor conference with ADBoard, or tumor conference without ADBoard.

Conditions

  • Hepatocellular Carcinoma
  • Fibrolamellar Hepatocellular Carcinoma
  • Cholangiocarcinoma, Perihilar
  • Intrahepatic Cholangiocarcinoma
  • Metastasis to Liver
  • Gallbladder Carcinoma

Interventions

OTHER

ADBoard

Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors

Sponsors & Collaborators

  • German Research Center for Artificial Intelligence

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Felix Krenzien · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05681949 on ClinicalTrials.gov